Toward immunomodulatory and anti-inflammatory properties of statins

Trends in Cardiovascular Medicine

Volumn 15, Issue 6, 2005, Pages 202-206

  Arnaud, Claire ^a   Braunersreuther, Vincent ^a   Mach, François ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b WHO Collaborating Centre in Education and Research in Human Reproduction   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CELLULAR IMMUNITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD40; CD40 LIGAND; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MAJOR HISTOCOMPATIBILITY COMPLEX; SIGNAL TRANSDUCTION; TH2 CELLS;

EID: 25144522575     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2005.07.002     Document Type: Review

References (53)

1. P Amarenco, J Labreuche, P Lavallee, and PJ Touboul Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis Stroke 35 2004 2902 2909
2. J Banchereau, F Briere, and C Caux Immunobiology of dendritic cells Annu Rev Immunol 18 1999 767 811
3. YV Bobryshev, and RS Lord Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions Cardiovasc Res 37 1998 799 810
4. TM Carlos, and JM Harlan Leukocyte-endothelial adhesion molecules Blood 84 1994 2068 2101
5. HK Chung, IK Lee, and H Kang Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells Exp Mol Med 34 2002 451 461
6. HM Colhoun, DJ Betteridge, and PN Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
7. JR Downs, M Clearfield, and S Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
8. ML Dustin, and TA Springer T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1 Nature 341 1989 619 624
9. M Endres, U Laufs, and Z Huang Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase Proc Natl Acad Sci USA 95 1998 8880 8885
10. M Essig, G Nguyen, and D Prie 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins Circ Res 83 1998 683 690
11. TM Foy, A Aruffo, and J Bajorath Immune regulation by CD40 and its ligand GP39 Annu Rev Immunol 14 1996 591 617
12. ME Gegg, R Harry, and D Hankey Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction J Immunol 174 2005 2327 2335
13. A Hall Rho GTPases and the actin cytoskeleton Science 279 1998 509 514
14. O Hernandez-Perera, D Perez-Sala, E Soria, and S Lamas Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells Circ Res 87 2000 616 622
15. JA Kobashigawa, S Katznelson, and H Laks Effect of pravastatin on outcomes after cardiac transplantation N Engl J Med 333 1995 621 627
16. B Kwak, F Mulhaupt, S Myit, and F Mach Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
17. B Kwak, F Mulhaupt, and N Veillard The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells Swiss Med Wkly 131 2001 41 46
18. E Lutgens, L Gorelik, and MJ Daemen Requirement for CD154 in the progression of atherosclerosis Nat Med 5 1999 1313 1316
19. F Mach, U Schonbeck, and GK Sukhova Reduction of atherosclerosis in mice by inhibition of CD40 signalling Nature 394 1998 200 203
20. Z Mallat, S Besnard, and M Duriez Protective role of interleukin-10 in atherosclerosis Circ Res 85 1999 e17 e24
21. DJ Maron, S Fazio, and MF Linton Current perspectives on statins Circulation 101 2000 207 213
22. DW McCarey, PI McInnes, and R Madhok Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial Lancet 363 2004 2015 2021
23. F Mulhaupt, CM Matter, and BR Kwak Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells Cardiovasc Res 59 2003 755 766
24. SE Nissen, EM Tuzcu, and P Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
25. LJ Pinderski, MP Fischbein, and G Subbanagounder Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes Circ Res 90 2002 1064 1071
26. JN Poynter, SB Gruber, and PD Higgins Statins and the risk of colorectal cancer N Engl J Med 352 2005 2184 2192
27. N Qizilbash, S Lewington, and S Duffy Cholesterol, diastolic blood pressure, and stroke. 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration Lancet 346 1995 1647 1653
28. PM Ridker, CP Cannon, and D Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
29. RS Rosenson, CC Tangney, and LC Casey Inhibition of proinflammatory cytokine production by pravastatin Lancet 353 1999 983 984
30. MM Sadeghi, A Tiglio, and K Sadigh Inhibition of interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors Transplantation 71 2001 1262 1268
31. Scandinvian Simvastatine Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
32. U Schonbeck, and P Libby The CD40/CD154 receptor/ligand dyad Cell Mol Life Sci 58 2001 4 43
33. U Schonbeck, F Mach, and P Libby CD154 (CD40 ligand) Int J Biochem Cell Biol 32 2000 687 693
34. U Schonbeck, N Gerdes, and N Varo Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells Circulation 106 2002 2888 2893
35. GG Schwartz, AG Olsson, and MD Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
36. PS Sever, B Dahlof, and NR Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
37. J Shepherd Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety Eur Heart J 16 1995 5 13
38. K Shimada, K Miyauchi, and H Daida Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench Circulation 109 2004 e213 e214
39. M Takemoto, K Node, and H Nakagami Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy J Clin Invest 108 2001 1429 1437
40. A Tonkin, P Aylward, and D Colquhoun Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
41. K Uyemura, LL Demer, and SC Castle Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis J Clin Invest 97 1996 2130 2138
42. L Van Aelst, and C D'Souza-Schorey Rho GTPases and signaling networks Genes Dev 11 1997 2295 2322
43. CJ Vaughan, MB Murphy, and BM Buckley Statins do more than just lower cholesterol Lancet 348 1996 1079 1082
44. CJ Vaughan, AM Gotto Jr., and CT Basson The evolving role of statins in the management of atherosclerosis J Am Coll Cardiol 35 2000 1 10
45. CJ Vaughan, N Delanty, and CT Basson Statin therapy and stroke prevention Curr Opin Cardiol 16 2001 219 224
46. T Vollmer, L Key, and V Durkalski Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
47. AH Wagner, M Gebauer, B Guldenzoph, and M Hecker 3-hydroxy-3- methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells Arterioscler Thromb Vasc Biol 22 2002 1784 1789
48. S Wassmann, U Laufs, and AT Baumer Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase Mol Pharmacol 59 2001 646 654
49. G Weitz-Schmidt, K Welzenbach, and V Brinkmann Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 2001 687 692
50. K Wenke, B Meiser, and J Thiery Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial Circulation 96 1997 1398 1402
51. K Wenke, B Meiser, and J Thiery Simvastatin initiated early after heart transplantation: 8-year prospective experience Circulation 107 2003 93 97
52. A Yilmaz, C Reiss, and O Tantawi HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis Atherosclerosis 172 2004 85 93
53. S Youssef, O Stuve, and JC Patarroyo The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78 84